Bettina Böttcher

No ORCID on file · 9 papers in corpus · active 2014-2025

Study types

  • article 7
  • erratum 1
  • other 1

Condition tags

  • endometriosis 6
  • dysmenorrhea 3
  • chronic_pelvic_pain 1
  • adenomyosis 1
  • dyspareunia 1
article 2025
·doi:10.1055/s-0045-1812539
article 2025
·doi:10.1055/s-0045-1812540
erratum 2022
Health and quality of life outcomes ·doi:10.1186/s12955-022-02027-4
article 2022
Health and quality of life outcomes ·doi:10.1186/s12955-022-01991-1

BACKGROUND: Endometriosis is often associated with severe dysmenorrhea, pelvic pain and dyspareunia and has a high impact on daily life as well as sexuality. Quality of partnership positively influences the course of various diseases and ab…

article 2020
·doi:10.1007/s12254-020-00626-9

Summary Fertility preservation in women has become well established over the last two decades. Nevertheless, options for cancer survivors need to be improved to regain ovarian functioning, ideally leading to pregnancy and live birth. Techni…

other 2017
Journal of pediatric and adolescent gynecology ·doi:10.1016/j.jpag.2017.01.014

STUDY OBJECTIVE: To study the safety and efficacy of dienogest 2 mg in adolescents with suspected endometriosis. DESIGN: A 52-week, open-label, single-arm study. SETTING: In 21 study centers, in 6 European countries. PARTICIPANTS: Adoles…

article 2015
Archives of gynecology and obstetrics ·doi:10.1007/s00404-015-3789-8
article 2014
Archives of gynecology and obstetrics ·doi:10.1007/s00404-014-3437-8

PURPOSE: In a series of publications, we had developed the concept that uterine adenomyosis and pelvic endometriosis as well as endometriotic lesions at distant sites of the body share a common pathophysiology with endometriosis constitutin…

article 2014
·doi:10.1093/humrep/deu205

STUDY QUESTION: What is the safe and pharmacodynamically active dose range for PDC31 (prostaglandin F2α receptor inhibitor) in patients with primary dysmenorrhea (PD)? SUMMARY ANSWER: The 1 mg/kg/h dose of PDC31 appears to be safe and poten…